Chugai May Not Win Race For $500m Neuromyelitis Optica Market, But May Best Soliris On Ease Of Use
Executive Summary
While Chugai’s satralizumab may not be odds on to win the race for approval, it may beat Alexion’s Soliris on ease of use with a regimen of subcutaneous application once a month versus Soliris’ fortnightly IV.
You may also be interested in...
Cash Injection Fuels Viela Bio's NMOSD FDA Filing
New and existing investors in Viela Bio have raised $75m in the latest funding round, allowing the AstraZeneca spin off to progress its NMOSD antibody to regulatory filing in the US. However, established companies may have stolen a march on commercializing a treatment.
Keeping Track Of Non-Oncology Review and Approval News: Erectile Dysfunction, Parkinson's, Cholesterol
The latest non-oncology drug development news and highlights from our US FDA Performance Tracker.
Chugai Looks Overseas As Challenges Loom At Home
Chugai sees continued overseas growth, helped by sales through parent and licensee Roche and a brace of novel products, as key to overcoming challenges at home over the next few years.